Recruiting
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
NCT07388524· Phase 3· National Cancer Institute (NCI)· Source
Contact: Anusha Chidharla (principal investigator)
Recruiting
Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
NCT07069699· Phase 1/2· National Cancer Institute (NCI)· Source
Contact: Aung M. Tun (principal investigator)
Recruiting
Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)
NCT06917911· Phase 2· National Cancer Institute (NCI)· Source
Contact: Jesus Gonzalez Lugo (principal investigator)
Recruiting
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
NCT07283939· Alliance for Clinical Trials in Oncology· Source
Contact: Gregory J. Crane (principal investigator)
Recruiting
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
NCT06769126· Phase 2· SWOG Cancer Research Network· Source
Contact: Anusha Chidharla (principal investigator)
Recruiting
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
NCT06661915· Phase 2· National Cancer Institute (NCI)· Source
Contact: Abdulraheem M. Yacoub (principal investigator)
Recruiting
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
NCT06860594· Phase 1· National Cancer Institute (NCI)· Source
Contact: Tolga Tuncer (principal investigator)
Recruiting
Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
NCT06696768· Phase 1· National Cancer Institute (NCI)· Source
Contact: Raed Al-Rajabi (principal investigator)
Recruiting
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
NCT06577441· Phase 2· National Cancer Institute (NCI)· Source
Contact: Jesus Gonzalez Lugo (principal investigator)
Recruiting
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
NCT06616584· Phase 2/3· SWOG Cancer Research Network· Source
Contact: Anusha Chidharla (principal investigator)
Recruiting
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
NCT06672146· Phase 2· National Cancer Institute (NCI)· Source
Contact: Kenneth Byrd (principal investigator)
Recruiting
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
NCT06287775· Phase 1/2· National Cancer Institute (NCI)· Source
Contact: Chao H. Huang (principal investigator)
Recruiting
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
NCT06116682· Phase 2· SWOG Cancer Research Network· Source
Contact: Anusha Chidharla (principal investigator)
Recruiting
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
NCT06317649· Phase 2· National Cancer Institute (NCI)· Source
Contact: Jesus Gonzalez Lugo (principal investigator)
Recruiting
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
NCT05554406· Phase 2· National Cancer Institute (NCI)· Source
Contact: Tara L. Lin (principal investigator)
Recruiting
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
NCT05554393· Phase 2· National Cancer Institute (NCI)· Source
Contact: Heather J. Male (principal investigator)
Recruiting
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
NCT06031688· Phase 2· SWOG Cancer Research Network· Source
Contact: Anusha Chidharla (principal investigator)
Recruiting
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
NCT06096844· Phase 3· National Cancer Institute (NCI)· Source
Recruiting
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
NCT05886049· Phase 1· National Cancer Institute (NCI)· Source
Contact: Jesus Gonzalez Lugo (principal investigator)
Recruiting
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
NCT05564390· Phase 2· National Cancer Institute (NCI)· Source
Contact: Tara L. Lin (principal investigator)
Recruiting
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
NCT06102902· Phase 1· National Cancer Institute (NCI)· Source
Recruiting
Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)
NCT06295367· ECOG-ACRIN Cancer Research Group· Source
Contact: Kristen Burkett (principal investigator)
Active, not recruiting
Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study
NCT05863351· Phase 3· ECOG-ACRIN Cancer Research Group· Source
Recruiting
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
NCT05803382· Phase 1· National Cancer Institute (NCI)· Source
Contact: Joaquina C. Baranda (principal investigator)
Recruiting
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
NCT05691491· Phase 1/2· National Cancer Institute (NCI)· Source
Contact: Raed Al-Rajabi (principal investigator)
Recruiting
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Myasthenia Gravis
NCT06064695· University of Missouri-Columbia· Source
Contact: Fairway Clinical and Translational Research Unit
Recruiting
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
NCT05642572· Phase 2· SWOG Cancer Research Network· Source
Contact: Anusha Chidharla (principal investigator)
Active, not recruiting
Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment
NCT05627245· Phase 1· National Cancer Institute (NCI)· Source
Recruiting
Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
NCT05172245· Phase 1· National Cancer Institute (NCI)· Source
Contact: Christopher Lominska (principal investigator)
Recruiting
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
NCT05080673· NRG Oncology· Source
Contact: Ajay Bansal (principal investigator)
Active, not recruiting
Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery
NCT04391049· Phase 1· NRG Oncology· Source
Active, not recruiting
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer
NCT04514497· Phase 1· National Cancer Institute (NCI)· Source
Recruiting
Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
NCT04633239· Phase 1· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer
NCT04216316· Phase 1/2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
NCT04172532· Phase 1/2· National Cancer Institute (NCI)· Source
Active, not recruiting
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
NCT04071236· Phase 1/2· National Cancer Institute (NCI)· Source
Recruiting
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
NCT04251052· NRG Oncology· Source
Contact: Andrea D. Jewell (principal investigator)
Active, not recruiting
Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
NCT04079712· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones
NCT04090398· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
NCI COVID-19 in Cancer Patients, NCCAPS Study
NCT04387656· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver
NCT04175912· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
NCT03914300· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study
NCT04166318· Phase 2· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs
NCT03896503· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
NCT04068103· Phase 2/3· NRG Oncology· Source
Active, not recruiting
Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer
NCT03816358· Phase 1· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma
NCT03854474· Phase 1/2· National Cancer Institute (NCI)· Source
Active, not recruiting
Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma
NCT03803774· Phase 1· National Cancer Institute (NCI)· Source
Active, not recruiting
Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer
NCT02595879· Phase 1· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
NCT03914612· Phase 3· National Cancer Institute (NCI)· Source
Showing 50 of 77.